Mobile

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensiti...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007420-26

A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensitivity in GERD patients with a partial response to PPI treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to compare a single dose of AZD1386 to placebo on esophageal sensitivity to thermal stimuli 1.5 hours post dose in GERD patients who are partial responders to PPI.

Critère d'inclusion

  • Gastroesophageal Reflux Disease (GERD) is the intended indication

Liens